Trial Profile
A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver metastases; Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 21 Mar 2024 Planned End Date changed from 3 Dec 2023 to 31 Jul 2024.
- 17 May 2022 Planned End Date changed from 30 Apr 2022 to 3 Dec 2023.
- 12 May 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Apr 2022.